Analysts' Top 5 Price Targets of February 25, 2026
Reading Time: 3 minutes
Alumis Inc [US0223071020] Stifel starts coverage with Buy and a price target of $44 (57% upside potential) The research firm emphasizes that next-generation TYK2 inhibitors, which achieve complete target coverage, have the potential to become an important class of oral drugs without a warning label (no Boxed Warning). This assessment is particularly supported by Alumis' topline data on Envudeucitinib for psoriasis, which, according to Stifel, supports the approach of full TYK2 coverage and justifies the positive rating of the stock. Additionally,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
